News

19 06, 2018

Global health insurance company Cigna covers HIFU

2018-06-19T14:59:20+00:00 June 19th, 2018|

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center --> Cigna, a a global health insurance service company based in the US, announced earlier this year that patients in the United States who have localized radio-recurrent prostate cancer are potentially eligible for insurance coverage for HIFU treatment. In other words, if a man was diagnosed with localized prostate cancer and then had radiation therapy then had the cancer return to the prostate and was diagnosed with localized recurrent prostate cancer, he may be eligible for coverage for having HIFU as a salvage option. It is important to note that coverage is policy specific so it may vary depending on the policy.  More information is available from Cigna [...]

12 06, 2018

It’s Men’s Health Month – A Focus on Prostate Cancer Prevention

2018-06-12T07:40:41+00:00 June 12th, 2018|

Is prostate cancer prevention possible? Urologist and prostate cancer specialist Dr. Michael Lazar talks about prevention and options for maintaining health after a cancer diagnosis. June is Men’s Health Month and the focus is on prostate cancer. Second only to skin cancer, prostate cancer is the most common cancer among men in the U.S. and the third most common cause of cancer related death today; lung cancer remains in the number one spot. Currently it is estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. Those at highest risk are men who have a family history of prostate cancer and black men, who are more than twice as likely to die from the disease as any other group. [...]

5 06, 2018

New study reviews PSA screening results following prostate cancer treatment

2018-06-05T11:03:37+00:00 June 5th, 2018|

A study assessed whether monitoring prostate cancer patients following treatment with a PSA test every three months versus once a year would provide a long-term survival benefit. Prostate cancer patients who were monitored more frequently after treatment did not live significantly longer than patients who were monitored once a year, according to study findings led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher. At the 2018 American Society of Clinical Oncology Annual Meeting in Chicago, researchers presented findings on Friday, June 1, from an analysis of data from nearly 10,500 prostate cancer patients in the United States from 2005 to 2010. The study's primary goal was to determine if more frequent monitoring with the prostate-specific antigen test after treatment improved patients' [...]

22 05, 2018

Fewer men are being screened, diagnosed, and treated for prostate cancer

2018-05-22T15:07:32+00:00 May 22nd, 2018|

A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. There is considerable debate surrounding the value of prostate cancer screening with prostate-specific antigen (PSA) testing, and the 2012 United States Preventive Services Task Force (USPSTF) recommendation against PSA testing lies at the center of this debate. This recommendation was made in part due to the potential harms -- such as erectile dysfunction and urinary incontinence -- associated with the treatment of clinically insignificant prostate cancer with radical prostatectomy or radiation. To examine the [...]

8 05, 2018

Who is the best candidate for HIFU prostate cancer treatment?

2018-05-08T08:30:04+00:00 May 8th, 2018|

Is HIFU Prostate Cancer Treatment for You? High Intensity Focused Ultrasound (HIFU) is a FDA approved non-invasive therapy for treating prostate cancer. Find out if you qualify for HIFU. HIFU may not be appropriate in every situation, but it is most effective for men who have early stage, localized prostate cancer that has not spread or metastasized outside the prostate HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. At the focal point of the sound waves (like a magnifying glass focusing the rays of [...]

24 04, 2018

New biopsy technology may identify better course of treatment for prostate cancer

2018-04-24T10:27:34+00:00 April 24th, 2018|

Prostate cancer is the second most common cancer in men and the fifth leading cause of death from cancer in men worldwide, according to 2012 numbers. While several viable treatment options for prostate cancer exist, many men affected with prostate cancer will not respond to first-line treatments. Researchers in the Department of Pharmaceutical Sciences at the Leslie Dan Faculty of Pharmacy, University of Toronto have developed a new technology for liquid biopsy to identify which patients may not respond to standard therapy before it is delivered. "Screening for drug resistance is key to improving treatment approaches for many cancers," said Shana Kelley, scientist and professor at the Leslie Dan Faculty of Pharmacy, University of Toronto. "It's important for patients not to be on a [...]

27 03, 2018

Wives of many prostate cancer sufferers challenged by the disease

2018-03-27T16:53:05+00:00 March 27th, 2018|

Many wives of advanced prostate cancer sufferers feel that their lives are being undermined by their husband’s illness, with nearly half reporting that their own health suffered. In addition a focus subgroup has revealed that many feel isolated and fearful, and worry about the role change in their lives as their husband’s cancer advances. This study, developed with the wives of men with metastatic prostate cancer who were being treated with hormone therapy, is amongst the first carried out on how prostate cancer affects the partners of sufferers. It was presented yesterday at the EAU conference in Copenhagen. Prostate cancer is the most common male cancer. Prostate cancer which metastisises to other parts of the body is often difficult or impossible to cure, and [...]

21 03, 2018

CEO Money interviews Dr. Michael Lazar

2018-03-21T15:08:56+00:00 March 21st, 2018|

HIFU (High-Intensity Focused Ultrasound) is a minimally-invasive surgical procedure recently introduced to the U.S, and only available in a few markets. Yet, its continued use by surgeons is leading to increased interest in the device’s effectiveness – especially amid a national trend that sees more younger men being diagnosed with early-stage prostate cancer each year. A slower-acting cancer than others, many older men (65+) choose not to seek treatment to avoid the often-harmful after-effects of surgery or radiation. However, younger men (40+), have little choice but to accept treatment, or face early death. In development for several years, HIFU offers hope where traditional surgical methods have left men scarred physically and mentally. A robotics-based device using focused sound waves to heat and [...]

13 03, 2018

Random PSA screening misses some aggressive and lethal prostate cancers

2018-03-13T10:59:50+00:00 March 13th, 2018|

UK researchers say that inviting men with no symptoms to a one-off PSA test for prostate cancer does not save lives. This from the largest ever prostate cancer trial conducted over 10 years by Cancer Research UK-funded scientists and published in the Journal of the American Medical Association (JAMA). Researchers at the Universities of Bristol and Oxford found that testing asymptomatic men with PSA detects some disease that would be unlikely to cause any harm but also misses some aggressive and lethal prostate cancers. This highlights the flaws of a single PSA test as a way to screen for prostate cancer, and shows the need to find more accurate ways to diagnose cancers that need to be treated. The CAP Trial, which spanned almost [...]

6 03, 2018

New PET scan targets copper in tumors to detect prostate cancer

2018-03-06T07:35:43+00:00 March 6th, 2018|

An Italian study featured in the March issue of The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (rising prostate-specific antigen [PSA] level). Copper tends to be more concentrated in tumors, making it a good imaging biomarker. For this study of 50 patients, researchers conducted PET/CT scans comparing the new imaging agent, copper-64 chloride (64CuCl2), with fluorine-18-choline (18F-Choline). Multiparametric magnetic resonance imaging (mpMRI) was also conducted. In addition to calculating the detection rate of each imaging modality, the biodistribution, kinetics of the lesions and radiation dosimetry of 64CuCl2 were evaluated. "This is the first time this novel agent has been compared with 18F-Choline-PET/CT in a considerable number of prostate [...]